Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain
- PMID: 1531593
- DOI: 10.1007/BF01253110
Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain
Abstract
The regional brain distribution and binding of the antipsychotic benzamide drug remoxipride was studied in the male rat. After i.v. injections of 3H-remoxipride (1 mumol.kg-1) more than 85% of the radioactivity was identified as authentic remoxipride in brain by using reversed-phase liquid chromatography. Autoradiographic and spectroscopic analysis showed that 3H-remoxipride was distributed relatively even in different brain areas, with exception of the following structures, which showed highest drug concentrations: the choroid plexus, septum, medial part of the caudate nucleus, different areas of the thalamus and hypothalamus situated close to the cerebral ventricles. A closer analysis of the autoradiograms showed a gradient of radioactivity extending from the cerebral ventricles to the deeper parts of the brain at 30 minutes after injections. After 60 minutes radioactivity was detected throughout all forebrain dopamine receptive areas. These findings suggest that remoxipride enters the cerebrospinal fluid (CSF) via the vascular bed of the choroid plexus and that it enters the brain interstitial fluid from the CSF. In the caudate nucleus, nucleus accumbens, olfactory tubercle and olfactory bulb 30-40% of the radioactivity was reduced by pretreatment with the dopamine D-2 selective drug raclopride. In addition, small, but significant, reductions (10-15%) of 3H-remoxipride derived radioactivity was found in the neocortex, hippocampus and the cerebellum, suggesting that remoxipride interacts with a D-2 receptor also in these cortical structures. Taken together, these studies show that after i.v. injections, 3H-remoxipride enters the brain primarily in unmetabolized form when given in doses that affect DA receptor mediated behaviours, that it distributes to most areas throughout the neuraxis and that it binds to D-2 receptors in different parts of the basal ganglia, neocortex, hippocampus and cerebellum.
Similar articles
-
Biochemical pharmacology of the atypical neuroleptic remoxipride.Acta Psychiatr Scand Suppl. 1990;358:27-36. doi: 10.1111/j.1600-0447.1990.tb05282.x. Acta Psychiatr Scand Suppl. 1990. PMID: 1978484 Review.
-
Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: evidence for selective labelling of dopamine receptors.Eur J Pharmacol. 1986 Jan 21;120(2):217-26. doi: 10.1016/0014-2999(86)90543-1. Eur J Pharmacol. 1986. PMID: 3948920
-
In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.J Neural Transm. 1989;76(1):13-28. doi: 10.1007/BF01244988. J Neural Transm. 1989. PMID: 2523467
-
The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.Neuroscience. 1994 Jul;61(2):269-83. doi: 10.1016/0306-4522(94)90230-5. Neuroscience. 1994. PMID: 7969908
-
Neuropharmacological and behavioural properties of remoxipride in the rat.Acta Psychiatr Scand Suppl. 1990;358:21-6. doi: 10.1111/j.1600-0447.1990.tb05281.x. Acta Psychiatr Scand Suppl. 1990. PMID: 1978483 Review.
Cited by
-
Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.CNS Drug Rev. 2001 Fall;7(3):265-82. doi: 10.1111/j.1527-3458.2001.tb00199.x. CNS Drug Rev. 2001. PMID: 11607043 Free PMC article. Review.
-
Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile.Psychopharmacology (Berl). 1994 Apr;114(3):383-91. doi: 10.1007/BF02249327. Psychopharmacology (Berl). 1994. PMID: 7855196
-
Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.Pharm Res. 2005 Jul;22(7):1011-37. doi: 10.1007/s11095-005-6039-0. Epub 2005 Jul 22. Pharm Res. 2005. PMID: 16028003 Review.
-
Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat.J Neural Transm Gen Sect. 1993;93(3):187-203. doi: 10.1007/BF01244996. J Neural Transm Gen Sect. 1993. PMID: 8217058
-
Biotransformation of post-clozapine antipsychotics: pharmacological implications.Clin Pharmacokinet. 2000 May;38(5):393-414. doi: 10.2165/00003088-200038050-00002. Clin Pharmacokinet. 2000. PMID: 10843459 Review.